Metabolic support during coronary reperfusion.

Area of Science:

• Cardiology
• Cardiovascular Research
• Medical Interventions

Background:

• Thrombolysis limitations in reducing infarct size.
• Potential for early metabolic interventions to improve outcomes.
• Need for evaluating metabolic therapies in acute myocardial infarction.

Purpose of the Study:

• To evaluate the effect of a 48-hour glucose-insulin-potassium (GIK) infusion on left ventricular function.
• To assess GIK's impact on infarct size and regional wall motion abnormalities in anterior infarction patients.
• To compare GIK therapy with placebo in patients receiving streptokinase.

Main Methods:

• Randomized controlled trial with 17 anterior infarction patients.
• Intravenous GIK infusion (48 hours) versus placebo.
• Assessment of global and regional ejection fractions via ventriculography at baseline and 10 days.
• All patients received streptokinase for thrombolysis.

Main Results:

• Significantly greater improvement in global ejection fraction in the GIK group (0.07 +/- 0.04) compared to placebo (-0.08 +/- 0.04) (p < 0.02).
• Markedly greater improvement in anterolateral (0.24 +/- 0.07 vs -0.02 +/- 0.04, p < 0.02) and diaphragmatic (0.08 +/- 0.08 vs -0.17 +/- 0.05, p < 0.005) segment ejection fractions with GIK.
• GIK reduced the size of segmental wall motion abnormalities.

Conclusions:

• Glucose-insulin-potassium infusion improves ventricular function in anterior infarction patients treated with streptokinase.
• Early GIK intervention can reduce infarct size and improve regional myocardial function.
• GIK represents a promising metabolic strategy to enhance outcomes post-thrombolysis.